Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Insulet

iStar Inc

Stocks of companies getting a direct tailwind from the COVID-19 pandemic aren't the only top performers in 2020 and over the last year.

3 "Non-Coronavirus Stocks" That Would Have Doubled Your Money Over the Last Year

Abbott Labs

Based on year-to-date returns, DexCom stands out with 43% gains vis-a-vis -9% decline for broader S&P 500. DexCom’s glucose monitoring devices, which can be used at-home, are seeing a surge in demand, amid movement restrictions and lockdown in various cities.

Best Medical Devices Stock: DexCom Or Abbott?

There's a burgeoning opportunity for body-worn devices in diabetes treatment, Dexcom Chief Executive Kevin Sayer said Wednesday as DXCM stock popped on its earnings beat.
The post Dexcom CEO Sees A Burgeoning Opportunity Amid Coronavirus Pandemic appeared first on Investor's Business Daily.

Dexcom CEO Sees A Burgeoning Opportunity Amid Coronavirus Pandemic

The COVID-19 outbreak didn't dampen demand for the company's popular G6 CGM system.

How DexCom's Q1 Results Trounced Wall Street Expectations

DexCom's (DXCM) CEO Kevin Sayer on Q1 2020 Results - Earnings Call Transcript

DexCom (DXCM) delivered earnings and revenue surprises of 340.00% and 14.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Tops Q1 Earnings and Revenue Estimates

Dexcom beat Wall Street's first-quarter expectations late Tuesday but pulled its 2020 outlook due to the coronavirus pandemic. As a result, DXCM stock surged in after-hours action.

Top-Ranked Diabetes Stock Outperforms Quarterly Views, But Pulls Outlook

Haemonetics

Perrigo

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

3 Medical Product Stocks Set to Beat This Earnings Season: DXCM, HAE & PRGO

Activision Blizzard

Chewy

Ecolab

Equifax

SBA Communications

Take-Two Interactive Software

You may have read stories about investment strategies tailored for down markets that have succeeded as the bull market in stocks ended this year.

Deep Dive: ‘We find innovation all over the place,’ says fund manager who’s beaten the S&P 500

DexCom's (DXCM) first-quarter performance is likely to reflect rising global awareness of the company's real-time CGM.

DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?

MarketAxess Holdings

These three businesses are handling the COVID-19 pandemic with ease.

3 Stocks Hitting All-Time Highs

Chemed

Eli Lilly

SAGE Therapeutics

ViewRay

Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.

Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results

DexCom (DXCM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

DexCom (DXCM) Jumps: Stock Rises 5.6%

Luminex

McKesson

Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.

3 MedTech Stocks Likely to Have Braved Coronavirus Blow in Q1

Dexcom stock popped into a buy zone Wednesday out of a cup with handle as shares of highly ranked Veeva Systems stock tried to do the same. Both are highly rated medical stocks.

Dexcom Stock Rallies Into Buy Zone As Veeva Systems Tries To Follow

Casa Systems

Limelight Networks

Murphy USA

Despite the economic disaster, a few stocks are likely to report better-than expected earnings results when they report their financial numbers this month.

Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month

Akamai Technologies

Amazon

Biogen

Centene

Electronic Arts

Equinix

Hormel Foods

ICU Medical

Johnson & Johnson

LogMeIn

Molina Healthcare

Netflix

NETGEAR

RingCentral

J. M. Smucker

Vertex Pharmaceuticals

Zscaler

The best large-cap industries are electronic gaming, drugmakers, gold, packaged foods, and healthcare plans.

Here Are The Best Large-Cap Stocks To Buy Now

NEW YORK, April  10, 2020  (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that DexCom, Inc. (Nasdaq: DXCM), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq: NDXX) prior to market open on Monday, April 20, 2020. DexCom, Inc. will replace American Airlines Group, Inc. (Nasdaq: AAL) in the indexes.

DexCom, Inc. to Join the NASDAQ-100 Index Beginning April 20, 2020

A Good Entry Point In DexCom

Shockwave Medical

There's no better time than the present to scoop up shares of these high-growth medical device makers.

Got $5,000 to Invest? 3 Great Medical Device Stocks to Buy Right Now

Axsome Therapeutics

Chemocentryx

Eidos Therapeutics Inc

Enphase Energy

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.

5 Guru Stocks That Beat the Market

Investor confidence is high in DexCom's (DXCM) stock, thanks to solid prospects.

Here's Why You Should Add DexCom (DXCM) to Your Portfolio Now

DexCom shares have soared 45% since March 18. The connected glucose monitoring systems firm is also expected to continue to grow and DXCM stock might be somewhat immune to the current coronavirus economic uncertainty.

Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now

Pfizer

DexCom and Pfizer are both absurdly cheap right now.

These 2 Stocks Are Trading at a Once-in-a-Lifetime Price

Clorox

eBay

Microsoft

Regeneron Pharmaceuticals

The U.S. government and Senate reached an agreement to inject $2 trillion of stimulus to boost the U.S. economy amid the coronavirus-induced turmoil.

US Government Reaches Deal on Stimulus Package: 5 Top Picks

News for DexCom Stock (DXCM)